drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Ianalumab (VAY736) is a fully human monoclonal IgG1 antibody that targets the BAFF receptor (BAFF-R; TNFRSF13C) on B cells, blocking BAFF/BLyS survival signaling and inducing antibody-dependent cellular cytotoxicity to deplete B cells. Administered subcutaneously to reduce autoreactive B-cell activity and autoantibody production in diffuse cutaneous systemic sclerosis.
nci_thesaurus_concept_id
C116788
nci_thesaurus_definition
A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.
drug_mesh_term
Ianalumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Fully human IgG1 monoclonal antibody against BAFF-R (TNFRSF13C) on B cells that blocks BAFF/BLyS survival signaling and induces Fc-mediated cytotoxicity (e.g., ADCC), resulting in B-cell depletion and reduced autoreactive B-cell activity and autoantibody production.
drug_name
Ianalumab
nct_id_drug_ref
NCT06470048